CONTEMPORARY APPROACHES TO THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS: A NARRATIVE REVIEW WITH REFERENCE TO DATA FROM UZBEKISTAN
- Authors
-
-
Rakhmatova Feruza Uraimovna
Assistant, Department of Hospital Therapy (Laboratory), Fergana Medical Institute of Public Health
Author
-
- Keywords:
- Postmenopausal osteoporosis, FRAX, DXA, trabecular bone score, denosumab, romosozumab, narrative review, Uzbekistan.
- Abstract
-
Postmenopausal osteoporosis remains a major cause of fragility fractures, loss of independence, and increasing healthcare costs. The aim of this narrative review was to summarize current evidence-based approaches to diagnosis, risk stratification, and treatment of postmenopausal osteoporosis, and to discuss their applicability in Uzbekistan. Sources were searched in PubMed/MEDLINE, PubMed Central, and on the official websites of the Endocrine Society, the International Society for Clinical Densitometry (ISCD), the National Osteoporosis Guideline Group (NOGG), and FRAXplus as of March 18, 2026. The review included clinical guidelines, official position statements, pivotal randomized trials, and Uzbekistan-specific epidemiological data. Contemporary diagnosis should rely on clinical risk factors, DXA, FRAX-based risk estimation, and, in selected cases, trabecular bone score and vertebral fracture assessment. Laboratory evaluation is primarily required to exclude secondary causes of bone loss and to ensure safe treatment selection. Antiresorptive drugs remain the mainstay for women at high fracture risk, whereas early anabolic or dual-action treatment followed by antiresorptive consolidation is appropriate for women at very high risk. For Uzbekistan, key priorities include broader access to FRAX and DXA, improved fracture ascertainment, and avoidance of unplanned denosumab discontinuation.
- References
-
1.
Kanis JA, Cooper C, Rizzoli R, Reginster JY, on behalf of the Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporosis International. 2019;30(1):3-44.
2.
Shoback D, Rosen CJ, Black DM, Cheung AM, Murad MH, Eastell R. Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society guideline update. Journal of Clinical Endocrinology and Metabolism. 2020;105(3):dgaa048.
3.
Lesnyak O, Ismailov S, Shakirova M, Alikhanova N, Zakroyeva A, Abboskhujaeva L, Johansson H, Harvey NC, McCloskey E, Kanis JA. Epidemiology of hip fracture and the development of a FRAX model for Uzbekistan. Archives of Osteoporosis. 2020;15:119. doi:10.1007/s11657-020-00792-7.
4.
International Society for Clinical Densitometry. 2023 ISCD Official Positions - Adult. Available at: https://iscd.org/official-positions-2023/. Accessed March 18, 2026.
5.
Silva BC, Broy SB, Boutroy S, Engelke K, Leslie WD, Schousboe JT. Fracture risk prediction by non-BMD DXA measures: the 2023 ISCD Official Positions, Part 2: trabecular bone score. Journal of Clinical Densitometry. 2024;27(2):101170.
- Downloads
- Published
- 2026-03-24
- Issue
- Vol. 2 No. 3 (2026)
- Section
- Articles
- License
-
This work is licensed under a Creative Commons Attribution 4.0 International License.
